Correction: Can fecal calprotectin be used as a biomarker of non-alcoholic fatty liver disease in obese adolescents?

Correction: Can fecal calprotectin be used as a biomarker of non-alcoholic fatty liver disease in obese adolescents?

Saved in:

Bibliographic Details
Main Authors:	Büşra Tetik Dinçer, Ayşe Merve Usta, Alev Kural, Nazlı Helvacı, Ahmet Uçar, Nafiye Urgancı
Format:	Article
Language:	English
Published:	BMC 2025-01-01
Series:	BMC Pediatrics
Online Access:	https://doi.org/10.1186/s12887-025-05392-3
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Can fecal calprotectin be used as a biomarker of non-alcoholic fatty liver disease in obese adolescents?
by: Büşra Tetik Dinçer, et al.
Published: (2024-12-01)

The role of partial splenic artery embolization in the management of refractory esophageal variceal bleeding due to portal vein thrombosis
by: Büşra Tetik Dinçer, et al.
Published: (2025-01-01)

Comparison of Fecal Calprotectin Methods for Predicting Relapse of Pediatric Inflammatory Bowel Disease
by: Saranya Kittanakom, et al.
Published: (2017-01-01)

Fecal Calprotectin Use in Inflammatory Bowel Disease and Beyond: A Mini-Review
by: Bashaar Alibrahim, et al.
Published: (2015-01-01)

Level of fecal neopterin and calprotectin in asymptomatic and symptomatic norovirus-infected children with malnutrition in Indonesia
by: Anisa Lailatul Fitria, et al.
Published: (2025-04-01)

The Utility of Fecal Calprotectin in the Real-World Clinical Care of Patients with Inflammatory Bowel Disease
by: Esmail Abej, et al.
Published: (2016-01-01)

Fecal Calprotectin: A Reliable Predictor of Mucosal Healing after Treatment for Active Ulcerative Colitis
by: Vendel Kristensen, et al.
Published: (2017-01-01)

Clinicians’ Guide to the Use of Fecal Calprotectin to Identify and Monitor Disease Activity in Inflammatory Bowel Disease
by: Brian Bressler, et al.
Published: (2015-01-01)

Correlation between fecal biomarkers and the presence of antineutrophil cytoplasmic antibodies with ulcerative colitis disease activity
by: Büşra Usta, et al.
Published: (2025-01-01)

Can different formulae be used in the diagnosis and staging of chronic kidney disease?
by: Çam Ergin, et al.
Published: (2024-10-01)

Systematic Review with Meta-Analysis: Fecal Calprotectin as a Surrogate Marker for Predicting Relapse in Adults with Ulcerative Colitis
by: Jiajia Li, et al.
Published: (2019-01-01)

Diagnostic Value of Fecal Calprotectin (S100 A8/A9) Test in Children with Chronic Abdominal Pain
by: Stanisław Pieczarkowski, et al.
Published: (2016-01-01)

Gut dysbiosis narrative in psoriasis: matched-pair approach identifies only subtle shifts correlated with elevated fecal calprotectin
by: Bayazit Yunusbayev, et al.
Published: (2025-01-01)

Alteration of fecal microbiome and metabolome by mung bean coat improves diet-induced non-alcoholic fatty liver disease in mice
by: Dianzhi Hou, et al.
Published: (2022-09-01)

Serum Calprotectin: A Potential Biomarker for Neonatal Sepsis
by: Lidia Decembrino, et al.
Published: (2015-01-01)

Antithyroid Antibodies and Thyroid Function in Pediatric Patients with Celiac Disease
by: Derya Kalyoncu, et al.
Published: (2015-01-01)

Faecal calprotectin concentration in children with coeliac disease
by: Anna Szaflarska-Popławska, et al.
Published: (2020-03-01)

The level of faecal calprotectin as a noninvasive biomarker of mucosal healing in children with ulcerative colitis
by: Edyta Szymańska, et al.
Published: (2020-12-01)

The concentration of calprotectin in the stools of children with diagnosed cystic fibrosis
by: Sabina Więcek, et al.
Published: (2016-03-01)

Faecal calprotectin in COVID-19 patients with intestinal symptoms
by: Walid Ellakany, et al.
Published: (2022-03-01)

Gastrointestinal manifestations and their relation to faecal calprotectin in children with autism
by: Hanan Galal Azouz, et al.
Published: (2021-12-01)

Ektacytometric examination of red blood cells’ morphodynamical features in diabetic nephropathy patients
by: Sari-Ak Duygu, et al.
Published: (2024-11-01)

Calprotectin and Calgranulin C as Biomarkers of Pancreatic Tumors: Baseline Levels and Level Changes after Surgery
by: Michal Holub, et al.
Published: (2019-01-01)

Diagnostic Possibilities of Determining the Level of Faecal Calprotectin in Clinical Practice
by: A. A. Sheptulin, et al.
Published: (2023-05-01)

Estimation of salivary IL-6 and calprotectin in patients with ulcerative colitis
by: Fadhel A. Abdullah, et al.
Published: (2024-12-01)

Improvement of non-alcoholic fatty liver disease treatment
by: P. I. Seliverstov, et al.
Published: (2014-10-01)

New aspects of non-alcoholic fatty liver disease
by: V. V. Tsukanov, et al.
Published: (2015-09-01)

Gut microbiome in non-alcoholic fatty liver disease
by: Anastasios Mpountouridis, et al.
Published: (2025-01-01)

Serum Calprotectin Level as an Inflammatory Marker in Newly Diagnosed Hypertensive Patients
by: Nergiz Bayrakci, et al.
Published: (2022-01-01)

Serum calprotectin in nonsegmental vitiligo: a possible marker of disease activity
by: Dalia A. Bassiouny, et al.
Published: (2025-01-01)

Usefulness of pemafibrate for non-alcoholic fatty liver disease with hypertriglyceridemia
by: Masahiro Kikuchi, et al.
Published: (2024-09-01)

Epidemiologic features of non-alcoholic fatty liver disease in Russia
by: O. M. Drapkina, et al.
Published: (2014-10-01)

Options of dyslipidemia treatment at non-alcoholic fatty liver disease
by: M. V. Mayevskaya, et al.
Published: (2018-08-01)

Pathogenic role of lipids in non-alcoholic fatty liver disease
by: Yu. O. Shulpekova
Published: (2012-02-01)

Fecal siderophore genes are potential biomarkers for ulcerative colitis
by: Jingshuang Yan, et al.
Published: (2025-01-01)

Peran Antioksidan pada Non Alcoholic Fatty Liver Disease (NAFLD)
by: Yusri Diane Jurnalis, et al.
Published: (2014-01-01)

Methodical approaches in experimental modelling of non-alcoholic fatty liver disease
by: N. V. Bivalkevich, et al.
Published: (2015-09-01)

Liver and Nutrition. An Optimal Diet for Non-Alcoholic Fatty Liver Disease
by: M. V. Mayevskaya, et al.
Published: (2018-11-01)

Non-Alcoholic Fatty Liver Disease in Cardiac Patients with Overweight and Obesity
by: I. V. Logacheva, et al.
Published: (2019-01-01)

Non-Alcoholic Fatty Liver Disease, Bile Acids and Intestinal Microbiota
by: R. V. Maslennikov, et al.
Published: (2018-09-01)